Leach Jacob Steven 4

What Happened
Jacob Steven Leach, President, CEO and a director of Dexcom, had 1,451 shares withheld by the company to satisfy tax withholding obligations related to the net settlement of restricted stock units (RSUs). The shares are reported as disposed at $71.90 per share, for a total value of $104,327. This was a tax-withholding (code F) transaction on May 22, 2026 and reported on a Form 4 filed May 27, 2026. Per the filing, this withholding is not an open-market sale.

Key Details

• Transaction date: May 22, 2026; price reported: $71.90; shares withheld/disposed: 1,451; total value: $104,327.
• Form 4 filed: May 27, 2026 (filed five days after the transaction). The filing appears later than the typical 2-business-day Form 4 window.
• Transaction code: F — shares withheld to cover tax withholding on net-settled RSUs (Footnote F1: not a sale by the reporting person).
• Footnote F2: Filing discloses 145,686 unvested RSUs included in reported holdings, with vesting tranches: 104,516 granted Mar 8, 2026 (vesting through Mar 8, 2029); 23,937 granted Mar 8, 2025 (vesting through Mar 8, 2028); 8,549 granted Mar 8, 2025 (vesting through Mar 8, 2027); and 8,684 granted Mar 8, 2024 (vesting through Mar 8, 2027).
• Footnote F3: Some shares are held by the Gregg Family Grandchildren's Trust (spouse is a trustee), indicating family-trust holdings.

Context
This was a routine net-settlement tax withholding on RSU vesting — the company retained shares to cover tax obligations rather than the insider making an open-market sale. Such withholdings are common and are administrative in nature; they do not necessarily signal a change in the insider’s view of the company.